Ardelyx™ develops therapeutics acting exclusively in the gastrointestinal tract and devoid of systemic exposure. Our drug candidates target important diseases, as well as pathologies with a specific inflammatory pathway. Our technology relies on non-absorbable small molecules with highly specific modes of action. The quasi-absence of systemic uptake greatly reduces potential side effects and toxicity while concentrating the drug at the locus of action, i.e. the GI tract.